500 patients67,039 observations150 daysLIVE

Patient P-03382

Synthetic patientONX-7 · Day 133 · 25–34 · M · baseline S01Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Improving
Discontinuation risk
41%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S01
  2. Day 99 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 102 GI-04 recommendedGI Support Protocol GI-04
  4. Day 103 Patient acceptedStarted GI-04 in the companion
  5. Day 111 GI symptom burden −29% vs expectedGI Support Protocol GI-04
  6. Day 117 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 99.

Primary contributors, last 14 days
  • Treatment adherence-10
  • Nutritional resilience+4
  • GI instability-2

What helped?

  • GI Support Protocol GI-04Day 102
    Result: symptom burden −29%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
61%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 82% showed improvement
  • median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
4.4/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.4/10
stable · +0.2 vs previous 14 d
Pessimism score
Daily log
5.8/10
worsening · +0.4 vs previous 14 d
Sleep quality
Wearable
39.4/100
stable · +1.0 vs previous 14 d
Libido
Daily log
2.8/10
stable · +0.0 vs previous 14 d
HRV
Wearable
40.2 ms
improving · +2.0 vs previous 14 d
Toxicity
Blood
45.4/100
worsening · +10.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 46 from the failing basin, 41 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 60%
  • DT-01 Dosing / Timing Recommendation
    82% improved among 11 similar · onset 5 d · confidence 60%
  • SC-12 Supportive Compound
    89% improved among 9 similar · onset 6 d · confidence 60%
  • More protein
    GI -6 next day on high-intake days · n 21
Would not help
  • AD-05 Adherence Support
    only 30% improved among 10 similar
  • Keep lactose low
    GI +5 next day on high-intake days · n 17
  • Keep histamine low
    GI +4.4 next day on high-intake days · n 23
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -6supporter · 95%
  • Lactose
    +5detractor · 95%
  • Histamine load
    +4.4detractor · 95%
  • Alcohol
    +1.7no signal · 38%
  • Dietary fat load
    -0.1no signal · 15%
  • Caffeine
    0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Autonomic recovery 65
    • WearableResting HR 80 bpm
    • Wearable3,486 steps/day
    • WearableShort sleep window
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Drug metabolism and exposure 55
    • DNADPYD *2A → slower clearance
    • BloodToxicity index 45
  • Butyrate / short-chain fatty acid production 45
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 25
    • BloodInflammatory load index 46
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 48/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
39 ms
Sleep
5.9 h
Steps
5,021
Resting HR
79 bpm
Daily log: GI score 43, nutritional resilience 49, adherence 78.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0338436%S0155
P-0307435%S0160
P-0338931%S0150
P-0338130%S0155
P-0344329%S0152
P-0325528%S01HY-01improved53
P-0309227%S0161
P-0305325%S0139
P-0317725%S0128
P-0301424%S0132
P-0335737%S02CR-01improved50
P-0309035%S02GI-04improved48